Mushroom-Based Supplements in Italy: Let's Open Pandora's Box
Mushrooms and derivates are well known to the scientific community for having different health benefits and exhibit a wide range of pharmacological activities, including lipid-lowering, antihypertensive, antidiabetic, antimicrobic, antiallergic, anti-inflammatory, anticancer, immunomodulating, neuro...
Gespeichert in:
Veröffentlicht in: | Nutrients 2023-02, Vol.15 (3), p.776 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 3 |
container_start_page | 776 |
container_title | Nutrients |
container_volume | 15 |
creator | Risoli, Samuele Nali, Cristina Sarrocco, Sabrina Cicero, Arrigo Francesco Giuseppe Colletti, Alessandro Bosco, Filippo Venturella, Giuseppe Gadaleta, Agata Gargano, Maria Letizia Marcotuli, Ilaria |
description | Mushrooms and derivates are well known to the scientific community for having different health benefits and exhibit a wide range of pharmacological activities, including lipid-lowering, antihypertensive, antidiabetic, antimicrobic, antiallergic, anti-inflammatory, anticancer, immunomodulating, neuroprotective and osteoprotective actions. In Europe, medical mushrooms are mainly marketed in the form of food supplements as single components or combined with other nutraceuticals. In this context, the first peculiarity that distinguishes it is the safety established through the "history of consumption" that characterizes that mushroom. However, the cultivation of medicinal mushrooms on a large scale is performed mainly in China, where most of the production facilities do not have internationally recognized good manufacturing practices, despite that many European companies that sell myotherapies are supplied by Chinese manufacturers. This is particularly evident in Italy, where an arsenal of mushroom products is marketed in the form of powders and extracts not always of ascertained origin and sometimes of doubtful taxonomic identification, and thus not meeting the quality criteria required. The growing interest in mycotherapy involves a strong commitment from the scientific community to propose supplements of safe origin and genetic purity as well as to promote clinical trials to evaluate its real effects on humans. The purpose of this research is to analyze different mushroom-based dietary supplements used in medicine as monotherapy on the Italian market and to evaluate their composition and quality. The molecular identification of the sequences with those deposited in GenBank allowed for identifying 6 out of 19 samples, matching with those deposited belonging to the species indicated in the label, i.e.,
(samples 1, 4, 12 and 18) and
(samples 5 and 10). Samples containing Ganoderma, labeled in the commercial product as
, showed sequences that showed homology of 100% and 99% with
and
. An additional investigation was carried out in order to determine the active fungal ingredients, such as ergosterol, aflatoxins, heavy metals, nicotine and total glucan. The results obtained and shown in the manuscript highlight how the data were not only in line with what is expected with respect to what is indicated in the labels. |
doi_str_mv | 10.3390/nu15030776 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9919834</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A743254250</galeid><sourcerecordid>A743254250</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-110e7a8cecb650f8aefeb18f7775d6a9d373fa43ab2bfa2a7ea43b383f25c7a13</originalsourceid><addsrcrecordid>eNptkV1L3jAUx8PYmPLozT7AKOxiIlTz1qYdKKg4JzxDwe06nKYnWmmTmrSi39486HxjyUVykt_555z8CfnC6I4QNd11MyuooEqVH8g6p4rnZSnFx1f7NbIZ4zVdDUVVKT6TNVEqxWTF18ne7zleBe-H_BAittnFPI49DuimmHUuO52gv_-RLXH6HrOzEV12Dq71AVJ46O82yCcLfcTNp3VB_v48_nP0K1-enZweHSxzI6mYcsYoKqgMmqYsqK0ALTasskqpoi2hboUSFqSAhjcWOChMQSMqYXlhFDCxIPuPuuPcDNiaVF6AXo-hGyDcaw-dfnvjuit96W91XbO6EjIJbD0JBH8zY5z00EWDfQ8O_Rw1T5WUTHLOE_rtHXrt5-BSeytK1lLKWrxQl9Cj7pz16V2zEtUHSgpeSJ5sWZCd_1Bptjh0xju0XTp_k7D9mGCCjzGgfe6RUb3yW7_4neCvr3_lGf3nrngAsoijIg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2774944493</pqid></control><display><type>article</type><title>Mushroom-Based Supplements in Italy: Let's Open Pandora's Box</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Risoli, Samuele ; Nali, Cristina ; Sarrocco, Sabrina ; Cicero, Arrigo Francesco Giuseppe ; Colletti, Alessandro ; Bosco, Filippo ; Venturella, Giuseppe ; Gadaleta, Agata ; Gargano, Maria Letizia ; Marcotuli, Ilaria</creator><creatorcontrib>Risoli, Samuele ; Nali, Cristina ; Sarrocco, Sabrina ; Cicero, Arrigo Francesco Giuseppe ; Colletti, Alessandro ; Bosco, Filippo ; Venturella, Giuseppe ; Gadaleta, Agata ; Gargano, Maria Letizia ; Marcotuli, Ilaria</creatorcontrib><description>Mushrooms and derivates are well known to the scientific community for having different health benefits and exhibit a wide range of pharmacological activities, including lipid-lowering, antihypertensive, antidiabetic, antimicrobic, antiallergic, anti-inflammatory, anticancer, immunomodulating, neuroprotective and osteoprotective actions. In Europe, medical mushrooms are mainly marketed in the form of food supplements as single components or combined with other nutraceuticals. In this context, the first peculiarity that distinguishes it is the safety established through the "history of consumption" that characterizes that mushroom. However, the cultivation of medicinal mushrooms on a large scale is performed mainly in China, where most of the production facilities do not have internationally recognized good manufacturing practices, despite that many European companies that sell myotherapies are supplied by Chinese manufacturers. This is particularly evident in Italy, where an arsenal of mushroom products is marketed in the form of powders and extracts not always of ascertained origin and sometimes of doubtful taxonomic identification, and thus not meeting the quality criteria required. The growing interest in mycotherapy involves a strong commitment from the scientific community to propose supplements of safe origin and genetic purity as well as to promote clinical trials to evaluate its real effects on humans. The purpose of this research is to analyze different mushroom-based dietary supplements used in medicine as monotherapy on the Italian market and to evaluate their composition and quality. The molecular identification of the sequences with those deposited in GenBank allowed for identifying 6 out of 19 samples, matching with those deposited belonging to the species indicated in the label, i.e.,
(samples 1, 4, 12 and 18) and
(samples 5 and 10). Samples containing Ganoderma, labeled in the commercial product as
, showed sequences that showed homology of 100% and 99% with
and
. An additional investigation was carried out in order to determine the active fungal ingredients, such as ergosterol, aflatoxins, heavy metals, nicotine and total glucan. The results obtained and shown in the manuscript highlight how the data were not only in line with what is expected with respect to what is indicated in the labels.</description><identifier>ISSN: 2072-6643</identifier><identifier>EISSN: 2072-6643</identifier><identifier>DOI: 10.3390/nu15030776</identifier><identifier>PMID: 36771482</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Aflatoxins ; Agaricales ; Antidiabetics ; Antihypertensives ; Chemical properties ; Clinical trials ; Composition ; Diabetes mellitus ; Dietary Supplements ; Ergosterol ; Europe ; Functional foods & nutraceuticals ; Fungiculture ; Glucan ; Good Manufacturing Practice ; Health aspects ; Heavy metals ; Homology ; Humans ; Inflammation ; Italy ; Lipids ; Manufacturers ; Materials ; Medical research ; Mushrooms ; Neuroprotection ; Particle size ; Reishi ; Ribosomal DNA</subject><ispartof>Nutrients, 2023-02, Vol.15 (3), p.776</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-110e7a8cecb650f8aefeb18f7775d6a9d373fa43ab2bfa2a7ea43b383f25c7a13</citedby><cites>FETCH-LOGICAL-c403t-110e7a8cecb650f8aefeb18f7775d6a9d373fa43ab2bfa2a7ea43b383f25c7a13</cites><orcidid>0000-0002-0511-5363 ; 0000-0002-8228-0258 ; 0000-0001-8646-5594 ; 0000-0002-4367-3884 ; 0000-0002-7080-8369 ; 0000-0002-6312-249X ; 0000-0002-6232-3775 ; 0000-0002-0146-5286</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9919834/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9919834/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36771482$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Risoli, Samuele</creatorcontrib><creatorcontrib>Nali, Cristina</creatorcontrib><creatorcontrib>Sarrocco, Sabrina</creatorcontrib><creatorcontrib>Cicero, Arrigo Francesco Giuseppe</creatorcontrib><creatorcontrib>Colletti, Alessandro</creatorcontrib><creatorcontrib>Bosco, Filippo</creatorcontrib><creatorcontrib>Venturella, Giuseppe</creatorcontrib><creatorcontrib>Gadaleta, Agata</creatorcontrib><creatorcontrib>Gargano, Maria Letizia</creatorcontrib><creatorcontrib>Marcotuli, Ilaria</creatorcontrib><title>Mushroom-Based Supplements in Italy: Let's Open Pandora's Box</title><title>Nutrients</title><addtitle>Nutrients</addtitle><description>Mushrooms and derivates are well known to the scientific community for having different health benefits and exhibit a wide range of pharmacological activities, including lipid-lowering, antihypertensive, antidiabetic, antimicrobic, antiallergic, anti-inflammatory, anticancer, immunomodulating, neuroprotective and osteoprotective actions. In Europe, medical mushrooms are mainly marketed in the form of food supplements as single components or combined with other nutraceuticals. In this context, the first peculiarity that distinguishes it is the safety established through the "history of consumption" that characterizes that mushroom. However, the cultivation of medicinal mushrooms on a large scale is performed mainly in China, where most of the production facilities do not have internationally recognized good manufacturing practices, despite that many European companies that sell myotherapies are supplied by Chinese manufacturers. This is particularly evident in Italy, where an arsenal of mushroom products is marketed in the form of powders and extracts not always of ascertained origin and sometimes of doubtful taxonomic identification, and thus not meeting the quality criteria required. The growing interest in mycotherapy involves a strong commitment from the scientific community to propose supplements of safe origin and genetic purity as well as to promote clinical trials to evaluate its real effects on humans. The purpose of this research is to analyze different mushroom-based dietary supplements used in medicine as monotherapy on the Italian market and to evaluate their composition and quality. The molecular identification of the sequences with those deposited in GenBank allowed for identifying 6 out of 19 samples, matching with those deposited belonging to the species indicated in the label, i.e.,
(samples 1, 4, 12 and 18) and
(samples 5 and 10). Samples containing Ganoderma, labeled in the commercial product as
, showed sequences that showed homology of 100% and 99% with
and
. An additional investigation was carried out in order to determine the active fungal ingredients, such as ergosterol, aflatoxins, heavy metals, nicotine and total glucan. The results obtained and shown in the manuscript highlight how the data were not only in line with what is expected with respect to what is indicated in the labels.</description><subject>Aflatoxins</subject><subject>Agaricales</subject><subject>Antidiabetics</subject><subject>Antihypertensives</subject><subject>Chemical properties</subject><subject>Clinical trials</subject><subject>Composition</subject><subject>Diabetes mellitus</subject><subject>Dietary Supplements</subject><subject>Ergosterol</subject><subject>Europe</subject><subject>Functional foods & nutraceuticals</subject><subject>Fungiculture</subject><subject>Glucan</subject><subject>Good Manufacturing Practice</subject><subject>Health aspects</subject><subject>Heavy metals</subject><subject>Homology</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Italy</subject><subject>Lipids</subject><subject>Manufacturers</subject><subject>Materials</subject><subject>Medical research</subject><subject>Mushrooms</subject><subject>Neuroprotection</subject><subject>Particle size</subject><subject>Reishi</subject><subject>Ribosomal DNA</subject><issn>2072-6643</issn><issn>2072-6643</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNptkV1L3jAUx8PYmPLozT7AKOxiIlTz1qYdKKg4JzxDwe06nKYnWmmTmrSi39486HxjyUVykt_555z8CfnC6I4QNd11MyuooEqVH8g6p4rnZSnFx1f7NbIZ4zVdDUVVKT6TNVEqxWTF18ne7zleBe-H_BAittnFPI49DuimmHUuO52gv_-RLXH6HrOzEV12Dq71AVJ46O82yCcLfcTNp3VB_v48_nP0K1-enZweHSxzI6mYcsYoKqgMmqYsqK0ALTasskqpoi2hboUSFqSAhjcWOChMQSMqYXlhFDCxIPuPuuPcDNiaVF6AXo-hGyDcaw-dfnvjuit96W91XbO6EjIJbD0JBH8zY5z00EWDfQ8O_Rw1T5WUTHLOE_rtHXrt5-BSeytK1lLKWrxQl9Cj7pz16V2zEtUHSgpeSJ5sWZCd_1Bptjh0xju0XTp_k7D9mGCCjzGgfe6RUb3yW7_4neCvr3_lGf3nrngAsoijIg</recordid><startdate>20230202</startdate><enddate>20230202</enddate><creator>Risoli, Samuele</creator><creator>Nali, Cristina</creator><creator>Sarrocco, Sabrina</creator><creator>Cicero, Arrigo Francesco Giuseppe</creator><creator>Colletti, Alessandro</creator><creator>Bosco, Filippo</creator><creator>Venturella, Giuseppe</creator><creator>Gadaleta, Agata</creator><creator>Gargano, Maria Letizia</creator><creator>Marcotuli, Ilaria</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TS</scope><scope>7X5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K6~</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0511-5363</orcidid><orcidid>https://orcid.org/0000-0002-8228-0258</orcidid><orcidid>https://orcid.org/0000-0001-8646-5594</orcidid><orcidid>https://orcid.org/0000-0002-4367-3884</orcidid><orcidid>https://orcid.org/0000-0002-7080-8369</orcidid><orcidid>https://orcid.org/0000-0002-6312-249X</orcidid><orcidid>https://orcid.org/0000-0002-6232-3775</orcidid><orcidid>https://orcid.org/0000-0002-0146-5286</orcidid></search><sort><creationdate>20230202</creationdate><title>Mushroom-Based Supplements in Italy: Let's Open Pandora's Box</title><author>Risoli, Samuele ; Nali, Cristina ; Sarrocco, Sabrina ; Cicero, Arrigo Francesco Giuseppe ; Colletti, Alessandro ; Bosco, Filippo ; Venturella, Giuseppe ; Gadaleta, Agata ; Gargano, Maria Letizia ; Marcotuli, Ilaria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-110e7a8cecb650f8aefeb18f7775d6a9d373fa43ab2bfa2a7ea43b383f25c7a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Aflatoxins</topic><topic>Agaricales</topic><topic>Antidiabetics</topic><topic>Antihypertensives</topic><topic>Chemical properties</topic><topic>Clinical trials</topic><topic>Composition</topic><topic>Diabetes mellitus</topic><topic>Dietary Supplements</topic><topic>Ergosterol</topic><topic>Europe</topic><topic>Functional foods & nutraceuticals</topic><topic>Fungiculture</topic><topic>Glucan</topic><topic>Good Manufacturing Practice</topic><topic>Health aspects</topic><topic>Heavy metals</topic><topic>Homology</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Italy</topic><topic>Lipids</topic><topic>Manufacturers</topic><topic>Materials</topic><topic>Medical research</topic><topic>Mushrooms</topic><topic>Neuroprotection</topic><topic>Particle size</topic><topic>Reishi</topic><topic>Ribosomal DNA</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Risoli, Samuele</creatorcontrib><creatorcontrib>Nali, Cristina</creatorcontrib><creatorcontrib>Sarrocco, Sabrina</creatorcontrib><creatorcontrib>Cicero, Arrigo Francesco Giuseppe</creatorcontrib><creatorcontrib>Colletti, Alessandro</creatorcontrib><creatorcontrib>Bosco, Filippo</creatorcontrib><creatorcontrib>Venturella, Giuseppe</creatorcontrib><creatorcontrib>Gadaleta, Agata</creatorcontrib><creatorcontrib>Gargano, Maria Letizia</creatorcontrib><creatorcontrib>Marcotuli, Ilaria</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Physical Education Index</collection><collection>Entrepreneurship Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nutrients</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Risoli, Samuele</au><au>Nali, Cristina</au><au>Sarrocco, Sabrina</au><au>Cicero, Arrigo Francesco Giuseppe</au><au>Colletti, Alessandro</au><au>Bosco, Filippo</au><au>Venturella, Giuseppe</au><au>Gadaleta, Agata</au><au>Gargano, Maria Letizia</au><au>Marcotuli, Ilaria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mushroom-Based Supplements in Italy: Let's Open Pandora's Box</atitle><jtitle>Nutrients</jtitle><addtitle>Nutrients</addtitle><date>2023-02-02</date><risdate>2023</risdate><volume>15</volume><issue>3</issue><spage>776</spage><pages>776-</pages><issn>2072-6643</issn><eissn>2072-6643</eissn><abstract>Mushrooms and derivates are well known to the scientific community for having different health benefits and exhibit a wide range of pharmacological activities, including lipid-lowering, antihypertensive, antidiabetic, antimicrobic, antiallergic, anti-inflammatory, anticancer, immunomodulating, neuroprotective and osteoprotective actions. In Europe, medical mushrooms are mainly marketed in the form of food supplements as single components or combined with other nutraceuticals. In this context, the first peculiarity that distinguishes it is the safety established through the "history of consumption" that characterizes that mushroom. However, the cultivation of medicinal mushrooms on a large scale is performed mainly in China, where most of the production facilities do not have internationally recognized good manufacturing practices, despite that many European companies that sell myotherapies are supplied by Chinese manufacturers. This is particularly evident in Italy, where an arsenal of mushroom products is marketed in the form of powders and extracts not always of ascertained origin and sometimes of doubtful taxonomic identification, and thus not meeting the quality criteria required. The growing interest in mycotherapy involves a strong commitment from the scientific community to propose supplements of safe origin and genetic purity as well as to promote clinical trials to evaluate its real effects on humans. The purpose of this research is to analyze different mushroom-based dietary supplements used in medicine as monotherapy on the Italian market and to evaluate their composition and quality. The molecular identification of the sequences with those deposited in GenBank allowed for identifying 6 out of 19 samples, matching with those deposited belonging to the species indicated in the label, i.e.,
(samples 1, 4, 12 and 18) and
(samples 5 and 10). Samples containing Ganoderma, labeled in the commercial product as
, showed sequences that showed homology of 100% and 99% with
and
. An additional investigation was carried out in order to determine the active fungal ingredients, such as ergosterol, aflatoxins, heavy metals, nicotine and total glucan. The results obtained and shown in the manuscript highlight how the data were not only in line with what is expected with respect to what is indicated in the labels.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36771482</pmid><doi>10.3390/nu15030776</doi><orcidid>https://orcid.org/0000-0002-0511-5363</orcidid><orcidid>https://orcid.org/0000-0002-8228-0258</orcidid><orcidid>https://orcid.org/0000-0001-8646-5594</orcidid><orcidid>https://orcid.org/0000-0002-4367-3884</orcidid><orcidid>https://orcid.org/0000-0002-7080-8369</orcidid><orcidid>https://orcid.org/0000-0002-6312-249X</orcidid><orcidid>https://orcid.org/0000-0002-6232-3775</orcidid><orcidid>https://orcid.org/0000-0002-0146-5286</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2072-6643 |
ispartof | Nutrients, 2023-02, Vol.15 (3), p.776 |
issn | 2072-6643 2072-6643 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9919834 |
source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
subjects | Aflatoxins Agaricales Antidiabetics Antihypertensives Chemical properties Clinical trials Composition Diabetes mellitus Dietary Supplements Ergosterol Europe Functional foods & nutraceuticals Fungiculture Glucan Good Manufacturing Practice Health aspects Heavy metals Homology Humans Inflammation Italy Lipids Manufacturers Materials Medical research Mushrooms Neuroprotection Particle size Reishi Ribosomal DNA |
title | Mushroom-Based Supplements in Italy: Let's Open Pandora's Box |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T08%3A29%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mushroom-Based%20Supplements%20in%20Italy:%20Let's%20Open%20Pandora's%20Box&rft.jtitle=Nutrients&rft.au=Risoli,%20Samuele&rft.date=2023-02-02&rft.volume=15&rft.issue=3&rft.spage=776&rft.pages=776-&rft.issn=2072-6643&rft.eissn=2072-6643&rft_id=info:doi/10.3390/nu15030776&rft_dat=%3Cgale_pubme%3EA743254250%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2774944493&rft_id=info:pmid/36771482&rft_galeid=A743254250&rfr_iscdi=true |